Logo image of JANX

JANUX THERAPEUTICS INC (JANX) Stock Fundamental Analysis

NASDAQ:JANX - Nasdaq - US47103J1051 - Common Stock - Currency: USD

23.24  -0.11 (-0.47%)

After market: 23.24 0 (0%)

Fundamental Rating

4

Overall JANX gets a fundamental rating of 4 out of 10. We evaluated JANX against 558 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for JANX as it has an excellent financial health rating, but there are worries on the profitability. JANX is valued quite expensively, but it does show have an excellent growth rating.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

JANX had negative earnings in the past year.
JANX had a negative operating cash flow in the past year.
In the past 5 years JANX always reported negative net income.
In the past 5 years JANX always reported negative operating cash flow.
JANX Yearly Net Income VS EBIT VS OCF VS FCFJANX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

JANX has a better Return On Assets (-7.40%) than 85.66% of its industry peers.
JANX's Return On Equity of -7.68% is amongst the best of the industry. JANX outperforms 88.89% of its industry peers.
Industry RankSector Rank
ROA -7.4%
ROE -7.68%
ROIC N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
JANX Yearly ROA, ROE, ROICJANX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K

1.3 Margins

JANX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
JANX Yearly Profit, Operating, Gross MarginsJANX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 -200 -400 -600 -800

More info and screens

8

2. Health

2.1 Basic Checks

JANX does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for JANX has been increased compared to 1 year ago.
Compared to 5 years ago, JANX has more shares outstanding
There is no outstanding debt for JANX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
JANX Yearly Shares OutstandingJANX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
JANX Yearly Total Debt VS Total AssetsJANX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

2.2 Solvency

An Altman-Z score of 22.10 indicates that JANX is not in any danger for bankruptcy at the moment.
The Altman-Z score of JANX (22.10) is better than 94.09% of its industry peers.
JANX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 22.1
ROIC/WACCN/A
WACC8.94%
JANX Yearly LT Debt VS Equity VS FCFJANX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 200M 400M 600M 800M 1B

2.3 Liquidity

A Current Ratio of 58.47 indicates that JANX has no problem at all paying its short term obligations.
With an excellent Current ratio value of 58.47, JANX belongs to the best of the industry, outperforming 99.46% of the companies in the same industry.
A Quick Ratio of 58.47 indicates that JANX has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 58.47, JANX belongs to the top of the industry, outperforming 99.46% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 58.47
Quick Ratio 58.47
JANX Yearly Current Assets VS Current LiabilitesJANX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

7

3. Growth

3.1 Past

JANX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -11.48%.
JANX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.01%.
JANX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 42.75% yearly.
EPS 1Y (TTM)-11.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.67%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%-100%

3.2 Future

JANX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.05% yearly.
The Revenue is expected to grow by 96.44% on average over the next years. This is a very strong growth
EPS Next Y-59.52%
EPS Next 2Y-44.99%
EPS Next 3Y-40.56%
EPS Next 5Y11.05%
Revenue Next Year-95.98%
Revenue Next 2Y-20.58%
Revenue Next 3Y-13.06%
Revenue Next 5Y96.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JANX Yearly Revenue VS EstimatesJANX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
JANX Yearly EPS VS EstimatesJANX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for JANX. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for JANX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
JANX Price Earnings VS Forward Price EarningsJANX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
JANX Per share dataJANX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

A cheap valuation may be justified as JANX's earnings are expected to decrease with -40.56% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-44.99%
EPS Next 3Y-40.56%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for JANX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

JANUX THERAPEUTICS INC

NASDAQ:JANX (6/25/2025, 8:00:02 PM)

After market: 23.24 0 (0%)

23.24

-0.11 (-0.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-08 2025-05-08/amc
Earnings (Next)08-05 2025-08-05/amc
Inst Owners114.02%
Inst Owner Change3.26%
Ins Owners1.42%
Ins Owner Change3.48%
Market Cap1.38B
Analysts85.26
Price Target85.22 (266.7%)
Short Float %19.95%
Short Ratio10.45
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.06%
Min EPS beat(2)5.55%
Max EPS beat(2)22.57%
EPS beat(4)3
Avg EPS beat(4)10.3%
Min EPS beat(4)-52.65%
Max EPS beat(4)65.71%
EPS beat(8)7
Avg EPS beat(8)19.78%
EPS beat(12)10
Avg EPS beat(12)17.26%
EPS beat(16)11
Avg EPS beat(16)-12.2%
Revenue beat(2)0
Avg Revenue beat(2)-100%
Min Revenue beat(2)-100%
Max Revenue beat(2)-100%
Revenue beat(4)1
Avg Revenue beat(4)190.7%
Min Revenue beat(4)-100%
Max Revenue beat(4)1036.58%
Revenue beat(8)5
Avg Revenue beat(8)157.53%
Revenue beat(12)9
Avg Revenue beat(12)168.73%
Revenue beat(16)13
Avg Revenue beat(16)204.38%
PT rev (1m)-0.86%
PT rev (3m)-5.86%
EPS NQ rev (1m)-2.4%
EPS NQ rev (3m)-8.05%
EPS NY rev (1m)-0.09%
EPS NY rev (3m)0.9%
Revenue NQ rev (1m)-50%
Revenue NQ rev (3m)-42.86%
Revenue NY rev (1m)-78.94%
Revenue NY rev (3m)-85.42%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 147.32
P/FCF N/A
P/OCF N/A
P/B 1.36
P/tB 1.36
EV/EBITDA N/A
EPS(TTM)-1.36
EYN/A
EPS(NY)-2.69
Fwd EYN/A
FCF(TTM)-0.79
FCFYN/A
OCF(TTM)-0.78
OCFYN/A
SpS0.16
BVpS17.11
TBVpS17.11
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.4%
ROE -7.68%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-13.05%
ROA(5y)-17.92%
ROE(3y)-14.45%
ROE(5y)-29.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 26.04%
Cap/Sales 5.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 58.47
Quick Ratio 58.47
Altman-Z 22.1
F-Score3
WACC8.94%
ROIC/WACCN/A
Cap/Depr(3y)293.31%
Cap/Depr(5y)445.07%
Cap/Sales(3y)33.73%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-11.48%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-26.67%
EPS Next Y-59.52%
EPS Next 2Y-44.99%
EPS Next 3Y-40.56%
EPS Next 5Y11.05%
Revenue 1Y (TTM)28.01%
Revenue growth 3Y42.75%
Revenue growth 5YN/A
Sales Q2Q%-100%
Revenue Next Year-95.98%
Revenue Next 2Y-20.58%
Revenue Next 3Y-13.06%
Revenue Next 5Y96.44%
EBIT growth 1Y-55.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-49.03%
EBIT Next 3Y-41.65%
EBIT Next 5YN/A
FCF growth 1Y8.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1.53%
OCF growth 3YN/A
OCF growth 5YN/A